Find Faculty
Daniel S Fierer, MD
img_Daniel S Fierer
PROFESSOR | Medicine, Infectious Diseases
email
Are you a patient?
View my
Provider Profile
Specialties
Infectious Disease

Dr. Fierer's research interests are focused on the study of acute Hepatitis C (HCV) infection in HIV-infected patients. Hepatitis C infection is highly prevalent in HIV-infected people, but Hepatitis C is rarely diagnosed during the acute phase (first 6 months) of infection and so little is known about the early course of Hepatitis C infection. Further, people who are already HIV-infected at the time they contract HCV infection may be at particular risk of having significant liver disease: a preliminary study in collaboration with Drs. Branch and Dieterich showed the presence of moderately advanced liver damage in HIV-infected people who have acute HCV infection. Dr. Fierer has initiated a larger study to evaluate HIV-infected patients referred by their physicians for acute HCV infection to further investigate the early effects of this infection on liver pathology, on the natural history of the disease, on the effectiveness of treatment, and of the mode of transmission.

MD, Yale University School of Medicine

Residency, Internal Medicine, University of California Medical Center San Diego

Fellowship, Infectious Disease, Warren Magnuson Clinical Center/National Institute of Health

Fellowship, Infectious Disease, University of CA at San Francisco Medical Center

Fellowship, Infectious Disease, Warren Magnuson Clinical Center/National Institute of Health

Certifications

American Board of Internal Medicine
45
Publications

Selected Publications

Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Arthur Y. Kim, Minhee Kang, Triin Umbleja, Estevão P. Nunes, Kristen M. Marks, Anne F. Luetkemeyer, Carrington Koebele, Chanelle Wimbish, Daniel S. Fierer, Dimas A. Kliemann, Sunil S. Solomon, Jens Kort, Jennifer J. Kiser, Georg M. Lauer, Raymond T. Chung, Leonard A. Sowah, Beverly L. Alston-Smith, David L. Wyles, Susanna Naggie, Shahadah Bailey, Stephanie Caruso, Allegra Cermak, Nuntisa Chotirosniramit, Nickson Chepkwony, Jagpreet Chhatwal, Dichaba Siane, Austin Glick, Cherisse Heirs, Laura Hovind, Faye Landsman, Kacey Matecki, Jennifer Mcclaren, Esmelda Montalban, Aspara Nair, Cynthia Parker, Michelle Seamann, Katherine Shin, Shannon Sloan, Dean Soko, Heather Sprenger, Vincent Vu, Frances Whalen, Gabriela Lisseth Umana Robleda, Lucimar Salgado, Jay Dwyer, Dennis Dentoni-Lasofsky, Cecilia Rivas Alfaro, Rebecca Fry, Celine Arar, Weill Cornell. Clinical Infectious Diseases

Improvements in substance use and social determinants of health associated with hepatitis C treatment initiation and sustained virologic response in opioid treatment programs. Andrew H. Talal, Raktim Mukhopadhyay, Valentina Veronesi, Arpan Dharia, Giovanni Saraceno, Daniel S. Fierer, Marianthi Markatou. Addictive Behaviors Reports

Neurocognitive trajectories in long COVID: Evidence from longitudinal analyses. Jacqueline H. Becker, Jia Li, Jenny J. Lin, Alex Federman, Emilia Bagiella, Minal S. Kale, Daniel Fierer, Logan Bartram, Juan P. Wisnivesky. Brain, Behavior, and Immunity - Health

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Fierer has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.